OrthoPediatrics Corp

KIDS remains in a Stage 4 decline with confirmed lower highs and lows and price below all key moving averages; there are no signs of selling exhaustion, volume and volatility support further downside, and both medium- and short-term signals align with a bearish continuation, favoring selling on breakdown into the next support area.

• ↑Q1 2026 revenue $59.4M (+13% YoY); full-year guidance $263–267M.
• ↑International revenue rose 22% YoY; expects it to outgrow domestic.
• ↓Negative earnings yield highlights difficulties in generating returns.